Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Reports Q2 Revenue $2.4M (2024)

Market Closed - Nasdaq Other stock markets 04:00:00 2024-08-19 pm EDT			5-day change	1st Jan Change
1.770 ^USD	-2.21%		-1.67%	+20.37%

Aug. 14	Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Reports Q2 Revenue $2.4M	MT
Aug. 12	BioAffinity Technologies, Inc. announced that it has received $1.302084 million in funding	CI

Summary

Quotes

Charts

News

Company

Financials

Valuation

Consensus

Latest news about bioAffinity Technologies, Inc.

Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Reports Q2 Revenue $2.4M	Aug. 14	MT
BioAffinity Technologies, Inc. announced that it has received $1.302084 million in funding	Aug. 11	CI
BioAffinity Raises Nearly $1.8 Million From Offerings	Aug. 05	MT
BioAffinity Technologies, Inc. announced that it expects to receive $1.302084 million in funding	Aug. 01	CI
BioAffinity Technologies, Inc. announced a financing transaction	Aug. 01	CI
Maxim Initiates bioAffinity Technologies at Buy With $6 Price Target	Jul. 23	MT
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q1 Revenue $2.4M	May. 15	MT
BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
BioAffinity Technologies, Inc. announced that it has received $2.624 million in funding	Mar. 19	CI
BioAffinity Technologies Closes $2.5 Million Equity Offerings	Mar. 08	MT
BioAffinity Technologies, Inc. announced that it expects to receive $2.624 million in funding	Mar. 05	CI
BioAffinity Technologies, Inc. Appoints Sandeep Bansal to Medical and Scientific Advisory Board	Feb. 06	CI
Transcript : BioAffinity Technologies, Inc. - Special Call	Jan. 09
BioAffinity Technologies, Inc. Appoints Jamie Platt, Ph.D., to its Board of Directors	Dec. 05	CI
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Posts Q3 Revenue $298,484	Nov. 14	MT
BioAffinity Technologies, Inc. Provides Earnings Guidance for the Year 2023 and for the Next 12 Months(fourth quarter 2023 to third quarter 2024)	Nov. 14	CI
BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
BioAffinity Technologies, Inc. Appoints Dallas J. Coleman as National Director of Sales	Nov. 06	CI
BioAffinity Technologies Files Registration Statement for Planned Offering of Units at Assumed Price of $1.62 a Unit	23-09-21	MT
BioAffinity Technologies, Inc. Announces Board Changes	23-09-20	CI
Transcript : BioAffinity Technologies, Inc. - Special Call	23-09-19
BioAffinity Technologies Unit Acquires Precision Pathology Services Laboratory Assets; Shares Rise	23-09-19	MT
Transcript : BioAffinity Technologies, Inc. - Special Call	23-09-17
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Reports Q2 Revenue $19,738	23-08-14	MT

Chart bioAffinity Technologies, Inc.

Duration

Period

Company Profile

bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.

Employees

Sector

Calendar

2024-11-10 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.770USD

Average target price

6.000USD

Spread / Average Target

+238.98%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Stock Market
Equities
BIAF Stock
News bioAffinity Technologies, Inc.
Earnings Flash (BIAF) BIOAFFINITY TECHNOLOGIES Reports Q2 Revenue $2.4M

Secure and Increase the Performance of your Investments with our Team of Experts at your Side Secure my Investments

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } gaEvent('adspv', 'InvestingChannel_v2', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '139917628');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });